Quantcast

Entyvio shows superiority over Humira in first head-to-head biologic study in ulcerative colitis

Takeda announced further results from the Varsity study, which demonstrated the superiority of the gut-selective biologic vedolizumab (Entyvio) to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira) in achieving the primary endpoint of clinical remission at week 52 in patients with moderately to severely active ulcerative colitis

Read more

Arena Pharmaceuticals testing etrasimod’s potential as an important future therapy for ulcerative colitis

Arena Pharmaceuticals has dosed first patients in a trial called ELEVATE UC 52, which is the first of two pivotal trials within the Phase 3 registrational program designated to test etrasimod 2 mg in subjects with moderately to severely active ulcerative colitis (UC).

Read more